Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115273 | 1.00 | MAPT (0.48) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL12615481 | 1.00 | MAPT (0.48) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL2590490 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL718199 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL5221398 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL8813869 | 0.91 | P2RX7 (0.47) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL6895557 | 0.91 | ALDH1A1 (0.50) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL8813866 | 0.91 | P2RX7 (0.47) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL7302285 | 0.90 | LTA4H (0.56) | MAPTLMNALNPEPLTA4HLAP3 | |
| SCHEMBL27403149 | 0.90 | MMP1 (0.46) | MAPTLMNALTA4HLAP3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110015978-B | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine | 康化（上海）新药研发有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-119368011-A | Polyamide composite film | 万华化学集团股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118084734-A | Preparation method of O- [2- [ [ tert-butoxycarbonyl ] amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine | 成都海杰亚医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-110637007-B9 | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-110637007-B | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-3634944-B1 | SYNTHESIS OF TYROSINE DERIVED DIPHENOL MONOMERS | MEDTRONIC INC (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-1996005167-A1 | DIMER DTPA DERIVATIVES AND THEIR METAL COMPLEXES, PHARMACEUTICALS CONTAINING THE SAME, THEIR USE IN DIAGNOSIS AND THERAPY AND PROCESS FOR PREPARING SAID COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
| EP-0527184-B1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES | AMERSHAM INT PLC (GB) | 1995-08-02 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| US-5380921-A | Enzyme inhibitors for endothelin converting enzyme for cardiovascular disorders and atherosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0623625-A1 | Aminophosphonic acid derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| EP-0527184-A1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES. | AMERSHAM INT PLC (GB) | 1993-02-17 | — | — | EP | disclosed |
| WO-1991017169-A1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES | AMERSHAM INTERNATIONAL PLC (GB) | 1991-11-14 | — | — | WO | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | MUC1, EGFR, LNPEP | MAPT 419/4885LMNA 1102/4885SLC7A5 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.